Last updated: February 20, 2026
What is NDC 00054-3090?
NDC 00054-3090 refers to a specific drug product listed in the National Drug Code Directory maintained by the FDA. It corresponds to Humira Pen (Adalimumab), a monoclonal antibody used primarily to treat autoimmune diseases including rheumatoid arthritis, Crohn’s disease, and psoriasis.
Market Overview
Market Size and Epidemiology
- Indications and Patient Population:
Humira treats conditions affecting an estimated 4 million Americans. Global prevalence for Crohn’s disease and rheumatoid arthritis exceeds 10 million cases.
- Therapeutic Area Competition:
Biologics like Humira face competition from other TNF inhibitors, such as Enbrel and Remicade, plus evolving biosimilars.
Competitive Landscape
- Brand Presence:
Humira held approximately 24% of the U.S. biologic market share in 2022, with estimated revenues of $20 billion.
- Biosimilar Competition:
Several biosimilars launched post-patent expiry starting in 2023, including Amjevita (Amgen) and Hyrimoz (Sandoz). Biosimilars typically reduce brand revenues by 20-40% within two years of launch.
- Regulatory Environment:
Patent protections in the U.S. expire in 2023, leading to increased biosimilar market entry and downward pressure on prices.
Market Trends
- Pricing Dynamics:
The annual list price for Humira in the U.S. averaged $70,000 per patient pre-2023. Pricing has decreased by an average of $10,000-15,000 per year in the last decade due to biosimilar competition.
- Usage Trends:
Prescription volume has stabilized due to biosimilar substitution but remains high because of disease severity and treatment inertia.
Price Projections
Short-Term (Next 1-2 Years)
- Biosimilar entry will lead to average price reductions of 25-30%, with some biosimilars priced 10-20% below Humira's original list price.
- List prices are expected to hover around $50,000 - $60,000 per year per patient by 2024-2025.
- Payers will increasingly promote biosimilar uptake, further pressuring brand prices.
Medium-Term (3-5 Years)
- Price erosion will likely stabilize at a 35-45% reduction each year post-biosimilar entry, driven by increased market share for biosimilars.
- Real-world average price per patient could fall to $30,000 - $40,000 annually.
- Market share for biosimilars could reach 60-70% of the total Humira-treated population.
Long-Term (5+ Years)
- Consolidation and patent exclusivity periods suggest a continued downward price trend.
- Forecasted average prices could decline to $20,000 - $25,000 annually in the next decade, aligning with biosimilar market penetration and competitive pricing.
Revenue Impact Scenarios
| Scenario |
Year 2023 |
Year 2025 |
Year 2030 |
| Baseline (No biosimilars) |
$20B* |
$20B* |
$20B* |
| Biosimilar market penetration (50%) |
$15B |
$10B |
$5B |
| Price reduction (30%) |
$14B |
$10B |
$4B |
*Note: Assumes continued use at pre-biosimilar pricing without market share loss, unlikely in reality.
Regulatory and Policy Factors
- Biosimilar approval pathway: The Biologics Price Competition and Innovation Act (BPCIA) enables biosimilar approvals, with the first biosimulaar approval happening in 2016.
- Price negotiation: The Inflation Reduction Act could affect Medicare and Medicaid drug prices, incentivizing further price declines.
- Market dynamics: Payer incentives to control costs will favor biosimilar adoption.
Key Takeaways
- NDC 00054-3090 is Humira (Adalimumab), a leading biologic with significant sales volume.
- Patent expiry in 2023 enables biosimilar entry, exerting downward pricing pressure.
- Short-term projections expect a 25-30% price reduction, with prices stabilizing around $50,000 - $60,000 annually.
- Long-term prices could decline to $20,000 - $25,000 per year as biosimilar market share grows.
- Revenue losses for the Humira brand could reach 50-70% over the next five years.
FAQs
Q1: How will biosimilar entry affect Humira’s sales volume?
A: Biosimilars are projected to capture 60-70% of the Humira-treated market within 3-5 years, reducing brand sales proportionally.
Q2: Are there regulatory hurdles for biosimilars?
A: Biosimilars are approved through FDA pathways that require comparable efficacy and safety, with no significant additional hurdles currently.
Q3: How does pricing differ between the U.S. and Europe?
A: European prices tend to be lower due to national negotiations and health system policies, often 30-50% below U.S. levels.
Q4: What is the potential for new indications to sustain price levels?
A: Additional approved indications could temporarily support higher prices but are unlikely to negate biosimilar price pressure.
Q5: Will innovation or new formulations impact the market?
A: Possible new formulations or delivery methods could temporarily boost sales but are unlikely to offset the biosimilar impact.
References
- IQVIA. (2022). Biologic Market Share and Sales Data.
- FDA. (2022). Biosimilar Approval Pathways.
- Express Scripts. (2022). Biologic and Biosimilar Pricing Trends.
- Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Policy Reports.
- Deloitte. (2022). Biologics and Biosimilars Market Outlook.
